NASH, PUBLICATIONS

First-in-Class FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase 3 Randomised Placebo Controlled Trial

By /

European Academy of Dermatology and Venereology (EADV) Congress 2025